Press Releases

Back to the list of press releases

Québec marks the inauguration of the Green Cross Biotherapeutics facilities in Montréal

Québec Life Sciences Strategy

Montréal, October 30, 2017 – Green Cross Biotherapeutics today inaugurated its new plasma fractionation plant in Technoparc Montréal, a $400-million project that will create more than 200 jobs. In 2014, the Québec government granted $25 million, which included a non-repayable financial contribution of $8 million and a $17-million loan in support of this project.


From left to right: Il-Sup Huh, President & CEO of Green Cross, Vanessa Marsan, MESI, Kim Ah-You, Investissement Québec, and Joon Han, Managing Director of Green Cross Biotherapeutics


Deputy Premier, Minister of Economy, Science and Innovation, and Minister responsible for the Digital Strategy Dominique Anglade, Minister of Health and Social Services Gaétan Barrette, and Minister responsible for Canadian Relations and the Canadian Francophonie, and Member for Saint-Laurent Jean-Marc Fournier took part in the inauguration and announced the allocation through Investissement Québec, acting as agent, of an additional $5-million loan under the ESSOR program. That support will help fund the increase in production capacity since the initial project.


Quotes :


“The opening of this new plasma fractionation plant is extremely important for Québec’s life sciences sector because this project is the largest investment in the past few years. Through the Québec Life Sciences Strategy, our government is ensuring that this ecosystem is complete and competitive. We are working to attract more major investment projects like that of Green Cross Biotherapeutics.”


Dominique Anglade, Deputy Premier, Minister of Economy, Science and Innovation, and Minister responsible for the Digital Strategy


“The Québec government is pleased to welcome this new player into Québec’s biopharmaceutical sector, with its plasma-derived products such as immunoglobulin and albumin. The Green Cross Biotherapeutics plant in Montréal will give us a safe, local supply of these products, which are essential to a multitude of treatments.”


Gaétan Barrette, Minister of Health and Social Services


“The arrival of this key player in the life sciences industry confirms the tremendous appeal of Québec and its metropolis to major investment projects. Our business environment is competitive and advantageous to foreign businesses wishing to settle here, just like Green Cross Biotherapeutics.”


Martin Coiteux, Minister of Municipal Affairs, Regions and Land Occupancy, Minister of Public Security, and Minister responsible for the Montréal region


“The establishment of Green Cross Biotherapeutics in Technoparc Montréal will create considerable economic benefits for the metropolis and the constituency of Saint-Laurent, as well as create hundreds of specialized jobs. This project will also help enhance the synergy among the different life sciences stakeholders in Montréal and throughout Québec.”


Jean-Marc Fournier, Member for Saint-Laurent, Minister responsible for Canadian Relations and the Canadian Francophonie, and Government House Leader




  • A Canadian subsidiary of South Korea’s Green Cross Corporation, Green Cross Biotherapeutics specializes in the development and manufacture of plasma-derived products.
  • The 2017–2027 Québec Life Sciences Strategy – Innovation Comes to Life aims to attract $4 billion in private investment to Québec by 2022 and to make Québec one of the top five North American poles in the life sciences sector by 2027.
  • ESSOR is a program that supports investment projects in Québec to enhance competitiveness, productivity, job creation and sustainable development.

To receive Investissement Québec press releases in real time, subscribe to the following RSS feed: Open a new window





Investissement Québec

1 844 474-6367